www亚洲午夜人美精片V区,国产精品乱码一区二区,亚洲另类黑,亚洲AV天天

熱門(mén)搜索: 50072ATAT1, GST-tag Recombinant 40520ATF2, GST-Tag Recombinant 31114GCN5 (727-837), His-tag Recombinant 50074GCN5 (KAT2A), FLAG-tag Recombinant 50071p300 (KAT3B), His-GST-tag Recombinant 11004ACHE, His-Tag Recombinant 50272BCL-2, His-Tag Recombinant 100077BCL2A1, His-Tag Recombinant 100080BCL2L10, His-Tag Recombinant 100091BCL2L2, His-Tag Recombinant 80113Caspase6, His-tag Recombinant 70000Caspase7, His-tag Recombinant 80114Caspase8, His-tag Recombinant 100543GPX4, FLAG-Tag Recombinant 100054MALT1, FLAG-Tag (Mouse) Recombinant 100637MCL-1 His-Tag (Mouse) Recombinant

產(chǎn)品展示/ Product display

您的位置:首頁(yè)  /  產(chǎn)品展示  /  技術(shù)服務(wù)  /  免疫學(xué)  /  BPS Bioscience的雙特異性抗體 & BiTE定制化服務(wù)

BPS Bioscience的雙特異性抗體 & BiTE定制化服務(wù)

  • 產(chǎn)品型號(hào):
  • 廠商性質(zhì):生產(chǎn)廠家
  • 更新時(shí)間:2023-12-19
  • 訪  問(wèn)  量:407
立即咨詢

聯(lián)系電話:

詳細(xì)介紹
  • 提供商:

    BPS Bioscience

  • 服務(wù)名稱:

    BPS Bioscience的雙特異性抗體 & BiTE定制化服務(wù)

CD3/CD19 BiTE® - Mechanism of Action

The CD3/CD19 BiTE® is a biopharmaceutical drug known as a Bi-specific T-cell engager for a second-line treatment for Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia. It binds to CD19 on cancer cells (e.g. Raji cells) and CD3 on T cells simultaneously, thus bringing T lymphocytes closer to cancer cells expressing specific cancer antigens (e.g. CD19). The binding event potentiates unstimulated T-cells and induces direct cytotoxicity against CD19+ cancer cells.

BPS has demonstrated the capability of assessing the functional activities of a commercially available CD3/CD19 BiTE® using our reporter cell lines, Jurkat/NFAT-luc or Jurkat/IL2-Luc.

Experimental Procedures

First, Jurkat effector cells with endogenous TCR/CD3 and transfected reporter NFAT-Luc or IL-2 promoter-Luc cells are incubated with increasing concentrations of the CD3/CD19 BiTE®in the presence or absence of CD19+ Raji cells. Secondly, the CD3/CD19 BiTE® simultaneously binds to TCR/CD3 on the Jurkat reporter cells and tumor antigen CD19 on the target Raji cells. Finally, its binding stimulates NFAT or IL-2 luciferase activity and the luciferase activity is assessed by our ONE-Step™ Luciferase Assay System.

圖片

BsAb-related Services

BPS offers customized services for generating BiTE® constructs and producing BiTE® antibodies, measuring the affinity for BiTE® antibody binding to antigen using interferometry (Gator™, Probe Life) or ELISA-based assay, and assessing T cell activation using reporter cell-based assays. BPS also offers over 200 cell lines expressing antigens on cancer cells on CHO or HEK293 cells, including our CD19-CHO Cell Line and several reporter cell lines including NFAT(Luc)/Jurkat cell lines for BiTE® construct evaluation in a reporter cell-based assay.

If you have further questions or would like to request a quote, please feel free to contact us.

References

留言詢價(jià)

留言框

  • 產(chǎn)品:

  • 您的單位:

  • 您的姓名:

  • 聯(lián)系電話:

  • 常用郵箱:

  • 省份:

  • 詳細(xì)地址:

  • 補(bǔ)充說(shuō)明:

  • 驗(yàn)證碼:

    請(qǐng)輸入計(jì)算結(jié)果(填寫(xiě)阿拉伯?dāng)?shù)字),如:三加四=7
關(guān)注公眾號(hào)

郵箱:infocn@bpsbioscience.com

傳真:

地址:上海靜安區(qū)

Copyright © 2025 BPS Bioscience Inc.版權(quán)所有   備案號(hào):   技術(shù)支持:化工儀器網(wǎng)

TEL:

掃碼加微信